PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-12.41%
Negative revenue growth while AGEN stands at 2257.45%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-12.41%
Negative gross profit growth while AGEN is at 690.21%. Joel Greenblatt would examine cost competitiveness or demand decline.
-27.47%
Negative EBIT growth while AGEN is at 379.01%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-27.47%
Negative operating income growth while AGEN is at 382.46%. Joel Greenblatt would press for urgent turnaround measures.
-27.92%
Negative net income growth while AGEN stands at 314.37%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-20.00%
Negative EPS growth while AGEN is at 303.08%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-20.00%
Negative diluted EPS growth while AGEN is at 292.77%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
6.47%
Share count expansion well above AGEN's 11.22%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
6.47%
Diluted share count expanding well above AGEN's 10.69%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-21.90%
Negative OCF growth while AGEN is at 336.47%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-21.77%
Negative FCF growth while AGEN is at 288.47%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2645.13%
Negative 10Y OCF/share CAGR while AGEN stands at 6407.98%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
92.60%
Below 50% of AGEN's 294.01%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
85.56%
3Y OCF/share CAGR under 50% of AGEN's 348.65%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
-3055.33%
Negative 10Y net income/share CAGR while AGEN is at 5363.93%. Joel Greenblatt sees a major red flag in long-term profit erosion.
92.82%
Below 50% of AGEN's 254.04%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
82.14%
Below 50% of AGEN's 349.98%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
1796.75%
10Y equity/share CAGR above 1.5x AGEN's 524.93%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-58.41%
Negative 5Y equity/share growth while AGEN is at 169.98%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
18.52%
Below 50% of AGEN's 114.88%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.03%
Asset growth well under 50% of AGEN's 127.58%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
-6.32%
We have a declining book value while AGEN shows 112.50%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-20.42%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
29.66%
R&D dropping or stable vs. AGEN's 13892.15%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
16.61%
SG&A growth well above AGEN's 28.44%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.